Genmab — Juni 2016
-
Danske: Darzalex-data for feinschmeckere styrker Genmabs sag
På weekendens kræftkonference i København blev der præsenteret detaljerede data fra endnu et fase 3-studie med Genmab-midlet Darzalex, som ifølge Danske Capitals seniorporteføljeforvalter blot føjer endnu mere til lægemidlets potentiale.
(medwatch.dk)
-
-
Hvorfor viser Genmab ikke Dara/Pom/Dex i deres pipeline? http://www.theoncologypharmacist.com/conference-correspondent/16580-daratumumab-plus-pomalidomide-and-dexamethasone-in-patients-with-relapsed-refractory-multiple-myeloma-results-of-a-4-arm-phase-1b-study
-
Pomalyst vises kun i multikombien! https://clinicaltrials.gov/ct2/show/NCT01998971?term=daratumumab+pomalyst&rank=1
-
Men var det ikke dara/pom/dex der viste så fantastiske resultater på ASH?
-
-
Det der blev fremlagt på ASH var Pom-armen af MMY1001 http://files.shareholder.com/downloads/AMDA-KPIBN/2227349525x0x865457/88AE6A8A-9ACE-4556-98E8-F20D51DBF87F/Genmab_RD_update_08Dec15_vFINAL_website.pdf side 42. Samt https://www.clinicaltrials.gov/ct2/show/NCT01998971?term=mmy1001&rank=1
-
OK tak Bulder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind